Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 7, 2010Circulation JournalOpen Access

Is There Evidence Supporting Coronary Revascularization in Patients With Left Ventricular Systolic Dysfunction?

View Full Paper
Ask AI
Bookmark
Share

Key result

The prognostic benefits of coronary revascularization in patients with chronic left ventricular dysfunction on optimal medical therapy remain uncertain, warranting a dedicated randomized trial guided by viability assessment.

Why the study?

Does coronary revascularization improve survival compared to optimal medical therapy in patients with chronic left ventricular systolic dysfunction due to coronary artery disease?

Population

Patients with chronic left ventricular systolic dysfunction due to coronary artery disease in the presence…

Comparison

Coronary revascularization (CABG or PCI) vs Optimal medical therapy with or without devices

Design

Review

Authors

EAEnrico AmmiratiOROrnella RimoldiPCPaolo G. Camici

Discussion

Loading...

Member takes

Overview

Revascularization benefit remains unproven in ischemic LV dysfunction on OMT; leaves open the value of viability-guided RCT.

Structured PICO

Does coronary revascularization improve survival compared to optimal medical therapy in patients with chronic left ventricular systolic dysfunction due to coronary artery disease?

P
Population
A review of clinical studies and meta-analyses evaluating the prognostic benefits of coronary revascularization in patients with coronary artery disease and chronic left ventricular systolic dysfunction.
I
Intervention
Coronary revascularization (CABG or PCI)
C
Comparator
Optimal medical therapy (OMT) with or without devices (CRT, ICD)
O
Outcome
Survival and prognostic benefits

This review highlights the lack of definitive randomized evidence supporting coronary revascularization over modern medical and device therapy in patients with ischemic left ventricular dysfunction, calling for a new dedicated clinical trial guided by viability imaging.

Limitations

  • Previous meta-analyses relied on retrospective, non-randomized studies.
  • Ongoing trials like STICH may have design limitations such as not mandating viability assessment for all patients.

Cite This Study

Ammirati et al. (2010) conducted a review in Coronary artery disease with left ventricular systolic dysfunction. Coronary revascularization vs. Optimal medical therapy was evaluated. The prognostic benefits of coronary revascularization in patients with chronic left ventricular dysfunction on optimal medical therapy remain uncertain, warranting a dedicated randomized trial guided by viability assessment.

synapsesocial.com/papers/6a88271c4c82be800eeb49b5https://doi.org/10.1253/circj.cj-10-1164
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction2009 · 727 citations
  2. 2Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study.1990 · 451 citations
  3. 3Coronary Intervention for Persistent Occlusion after Myocardial Infarction2006 · 739 citations
  4. 4The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure2005 · 6,311 citations
  5. 5Optimal Medical Therapy with or without PCI for Stable Coronary Disease2007 · 4,721 citations